Cyclical expression of EBV latent membrane protein 1 in EBV-transformed B cells underpins heterogeneity of epitope presentation and CD8+ T cell recognition

Journal of Immunology

Volumn 182, Issue 4, 2009, Pages 1919-1928

  Brooks, Jill M ^a   Lee, Steven P ^a   Leese, Alison M ^a   Thomas, Wendy A ^a   Rowe, Martin ^a   Rickinson, Alan B ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; LATENT MEMBRANE PROTEIN 1; CYTOKINE; EBV ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN BARR VIRUS; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; MATRIX PROTEIN;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL GROWTH; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL LINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; VIRUS INFECTION; BIOSYNTHESIS; CELL LINE; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; VIROLOGY; VIRUS CELL TRANSFORMATION; WESTERN BLOTTING;

ANTIGEN PRESENTATION; B-LYMPHOCYTES; BLOTTING, WESTERN; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, VIRAL; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, T-LYMPHOCYTE; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LYMPHOCYTE ACTIVATION; VIRAL MATRIX PROTEINS;

EID: 61449188280     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0713607     Document Type: Article

References (52)

1. Khanna, R., and S. R. Burrows. 2000. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Annu. Rev. Microbiol. 54: 19-48.
2. Rickinson, A. B., D. J. Moss, D. J. Allen, L. E. Wallace, M. Rowe, and M. A. Epstein. 1981. Reactivation of Epstein-Barr virus-specific cytotoxic T cells by in vitro stimulation with the autologous lymphoblastoid cell line. Int. J. Cancer 27: 593-601.
3. Wallace, L. E., A. B. Rickinson, M. Rowe, D. J. Moss, D. J. Allen, and M. A. Epstein. 1982. Stimulation of human lymphocytes with irradiated cells of the autologous Epstein-Barr virus-transformed cell line: I. Virus-specific and non-specific components of the cytotoxic response. Cell. Immunol. 67: 129-140.
4. Murray, R. J., M. G. Kurilla, J. M. Brooks, W. A. Thomas, M. Rowe, E. Kieff, and A. B. Rickinson. 1992. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J. Exp. Med. 176: 157-168.
5. Khanna, R., S. R. Burrows, M. G. Kurilla, C. A. Jacob, I. S. Misko, T. B. Sculley, E. Kieff, and D. J. Moss. 1992. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J. Exp. Med. 176: 169-176.
6. Levitskaya, J., M. Coram, V. Levitsky, S. Imreh, P. M. Steigerwald-Mullen, G. Klein, M. G. Kurilla, and M. G. Masucci. 1995. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375: 685-688.
7. Levitskaya, J., A. Sharipo, A. Leonchiks, A. Ciechanover, and M. G. Masucci. 1997. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc. Natl. Acad. Sci. USA 94: 12616-12621.
8. Hislop, A. D., G. S. Taylor, D. Sauce, and A. B. Rickinson. 2007. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu. Rev. Immunol. 25: 587-617.
9. + T cell response: lessons from the EBV nuclear antigen EBNA1. J. Immunol. 165: 7078-7087.
10. Hill, A. B., S. P. Lee, J. S. Haurum, N. Murray, Q.-Y. Yao, M. Rowe, N. Signoret, A. B. Rickinson, and A. J. McMichael. 1995. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV) nuclear antigens fail to lyse the EBV-transformed B lymphoblastoid cell lines against which they were raised. J. Exp. Med. 181: 2221-2228.
11. + T cells recognize EBV antigen but poorly kill autologous EBV-infected B lymphoblasts. J. Immunol. 159: 1844-1852.
12. Kersten, M. J., M. R. Klein, A. M. Holwerda, F. Miedema, and M. H. van Oers. 1997. Epstein-Barr virus-specific cytotoxic T cell responses in HIV-1 infection: different kinetics in patients progressing to opportunistic infection or non-Hodgkin's lymphoma. J. Clin. Invest. 99: 1525-1533.
13. Lee, S. P., J. M. Brooks, H. Al-Jarrah, W. A. Thomas, T. A. Haigh, G. S. Taylor, S. Humme, A. Schepers, W. Hammerschmidt, J. L. Yates, et al. 2004. CD8 T cell recognition of endogenously expressed Epstein-Barr virus nuclear antigen 1. J. Exp. Med. 199: 1409-1420.
14. Valitutti, S., S. Muller, M. Dessing, and A. Lanzavecchia. 1996. Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J. Exp. Med. 183: 1917-1921.
15. + T cell effector activity is dictated by cognate peptide concentration. J. Immunol. 172: 6407-6417.
16. Hong, G., K., H. J. Delecluse, H. Gruffat, T. E. Morrison, W. H. Feng, A. Sergeant, and S. C. Kenney. 2004. The BRRF1 early gene of Epstein-Barr virus encodes a transcription factor that enhances induction of lytic infection by BRLF1. J. Virol. 78: 4983-4992.
17. Bornkamm, G. W., C. Berens, C. Kuklik-Roos, J. M. Bechet, G. Laux, J. Bachl, M. Korndoerfer, M. Schlee, M. Hölzel, A. Malamoussi, et al. 2005. Stringent doxycycline-dependent control of gene activities using an episomal one-vector system. Nucleic Acids Res. 33: e137.
18. Lee, S. P., R. J. Tierney, W. A. Thomas, J. M. Brooks, and A. B. Rickinson. 1997. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. J. Immunol. 158: 3325-3334.
19. McLaren, J., M. Rowe, and P. Brennan. 2007. Epstein-Barr virus induces a distinct form of DNA-bound STAT1 compared with that found in interferon-stimulated B lymphocytes. J. Gen. Virol. 88: 1876-1886.
20. Stam, N. J., H. Spits, and H. L. Ploegh. 1986. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J. Immunol. 137: 2299-2306.
21. Rowe, M., H. S. Evans, L. S. Young, K. Hennessy, E. Kieff, and A. B. Rickinson. 1987. Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells. J. Gen. Virol. 68: 1575-1586.
22. Fruehling, S., S. K. Lee, R. Herrold, B. Frech, G. Laux, E. Kremmer, F. A. Grasser, and R. Longnecker. 1996. Identification of latent membrane protein 2A (LMP2A) domains essential for the LMP2A dominant-negative effect on B-lymphocyte surface immunoglobulin signal transduction. J. Virol. 70: 6216-6226.
23. Rowe, M., A. L. Lear, D. Croom-Carter, A. H. Davies, and A. B. Rickinson. 1992. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J. Virol. 66: 122-131.
24. Rao, A., C. Luo, and P. G. Hogan. 1997. Transcription factors of the NFAT family: regulation and function. Annu. Rev. Immunol. 15: 707-747.
25. Zhan, X., B, Brown, K. S. Slobod, and J. L. Hurwitz. 2003. Inhibition of ex vivo-expanded cytotoxic T-lymphocyte function by high-dose cyclosporine. Transplantation 76: 739-741.
26. Kataoka, T., N. Shinohara, H. Takayama, K. Takaku, S. Kondo, S. Yonehara, and K. Nagai. 1996. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. J. Immunol. 156: 3678-3686.
27. Milner, A. E., D. H. Palmer, E. A. Hodgkin, A. G. Eliopoulos, P. G. Knox, C. J. Poole, D. J. Kerr, and L. S. Young. 2002. Induction of apoptosis by chemotherapeutic drugs: the role of FADD in activation of caspase-8 and synergy with death receptor ligands in ovarian carcinoma cells. Cell Death Differ. 9: 287-300.
28. Keating, S., S. Prince, M. Jones, and M. Rowe. 2002. The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and II molecules. J. Virol. 76: 8179-8188.
29. Ressing, M. E., S, E. Keating, D. van Leeuwen, D. Koppers-Lalic, I. Y. Pappworth, E. J. Wiertz, and M. Rowe. 2005. Impaired transporter associated with antigen processing-dependent peptide transport during productive EBV infection. J. Immunol. 174: 6829-6838.
30. Rowe, M., R. Khanna, C. A. Jacob, V. Argaet, A. Kelly, S. Powis, M. Belich, D. Croom Carter, S. Lee, S. R. Burrows, et al. 1995. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression. Eur. J. Immunol. 25: 1374-1384.
31. Sykulev, Y., M. Joo, I. Vturina, T. J. Tsomides, and H. N. Eisen. 1996. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 4: 565-571.
32. Faroudi, M., C. Utzny, M. Salio, V. Cerundolo, M. Guiraud, S. Muller, and S. Valitutti. 2003. Lytic versus stimulatory synapse in cytotoxic T lymphocyte/ target cell interaction: manifestation of a dual activation threshold. Proc. Natl. Acad. Sci. USA 100: 14145-14150.
33. Purbhoo, M. A., D. J. Irvine, J. B. Huppa, and M. M. Davis. 2004. T cell killing does not require the formation of a mature immunological synapse. Nat. Immunol. 5: 524-530.
34. Lee, Y. R., I. H. Yang, Y. H. Lee, S. A. Im, S. Song, H. Li, K. Han, K. Kim, S. K. Eo, and C. K. Lee. 2005. Cyclosporin A and tacrolimus, but not rapamycin, inhibit MHC-restricted antigen presentation pathways in dendritic cells. Blood 105: 3951-3955.
35. Davenport, M. G., and J. S. Pagano. 1999. Expression of EBNA-1 mRNA is regulated by cell cycle during Epstein-Barr virus type I latency. J. Virol. 73: 3154-3161.
36. Baichwal, V. R., and B. Sugden. 1987. Posttranslational processing of an Epstein-Barr virus-encoded membrane protein expressed in cells transformed by Epstein-Barr virus. J. Virol. 61: 866-875.
37. Mann, K. P., and D. Thorley-Lawson. 1987. Posttranslational processing of the Epstein-Barr virus-encoded p63/LMP protein. J. Virol. 61: 2100-2108.
38. Lam, N., M. L. Sandberg, and B. Sugden. 2004. High physiological levels of LMP1 result in phosphorylation of eIF2α in Epstein-Barr virus-infected cells. J. Virol. 78: 1657-1664.
39. Floettmann, J. E., K. Ward, A. B. Rickinson, and M. Rowe. 1996. Cytostatic effect of Epstein-Barr virus latent membrane protein-1 analyzed using tetracycline-regulated expression in B cell lines. Virology 223: 29-40.
40. Kaykas, A., and B. Sugden. 2000. The amino-terminus and membrane-spanning domains of LMP-1 inhibit cell proliferation. Oncogene 19: 1400-1410.
41. Lee, D. Y., and B. Sugden. 2008. The LMP1 oncogene of EBV activates PERK and the unfolded protein response to drive its own synthesis. Blood 15: 2280-2289.
42. Pai, S., B. J. O'Sullivan, L. Cooper, R. Thomas, and R. Khanna. 2002. RelB nuclear translocation mediated by the C-terminal activator regions of Epstein-Barr virus-encoded latent membrane protein 1 and its effect on antigen-presenting function in B cells. J. Virol. 76: 1914-1921.
43. Lee, D. Y., and B. Sugden. 2008. The latent membrane protein 1 oncogene modifies B-cell physiology by regulating autophagy. Oncogene 227: 2833-2842.
44. Delecluse, H.-J., E. Kremmer, J.-P. Rouault, C. Cour, G. Bornkamm, and F. Berger. 1995. The expression of Epstein-Barr virus latent proteins is related to the pathological features of post-transplant lymphoproliferative disorders. Am. J. Pathol. 146: 1113-1120.
45. Brink, A. A., D. F. Dukers, A. J. van den Brule, J. J. Oudejans, J. M. Middeldorp, C. J. Meijer, and M. Jiwa. 1997. Presence of Epstein-Barr virus latency type III at the single cell level in post-transplantation lymphoproliferative disorders and AIDS related lymphomas. J. Clin. Pathol. 50: 911-918.
46. Rooney, C. M., C. A. Smith, C. Y. Ng, S. K. Loftin, J. W. Sixbey, Y. Gan, D. K. Srivastava, L. C. Bowman, R. A. Krance, M. K. Brenner, and H. E. Heslop. 1998. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92: 1549-1555.
47. Khanna, R., S. Bell, M. Sherritt, A. Galbraith, S. R. Burrows, L. Rafter, B. Clarke, R. Slaughter, M. C. Falk, J. Douglass, et al. 1999. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc. Natl. Acad. Sci. USA 96: 10391-10396.
48. Haque, T., G. M. Wilkie, C. Taylor, P. L. Amlot, P. Murad, A. Iley, D. Dombagoda, K. M. Britton, A. J. Swerdlow, and D. H. Crawford. 2002. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 360: 436-442.
49. Kurth, J., T. Spieker, J. Wustrow, G. J. Strickler, L. M. Hansmann, K. Rajewsky, and R. Küppers. 2000. EBV-infected B cells in infectious mononucleosis: viral strategies for spreading in the B cell compartment and establishing latency. Immunity 13: 485-495.
50. Chiang, A. K., Q. Tao, G. Srivastava, and F. C. Ho. 1996. Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease. Int. J. Cancer 68: 285-290.
51. Niedobitek, G., L. S. Young, C. K. Sam, L. Brooks, U. Prasad, and A. B. Rickinson. 1992. Expression of Epstein-Barr virus genes and of lymphocyte activation molecules in undifferentiated nasopharyngeal carcinomas. Am. J. Pathol. 140: 879 - 887.
52. Niedobitek, G., A. Agathanggelou, and J. M. Nicholls. 1996. Epstein-Barr virus infection and the pathogenesis of nasopharyngeal carcinoma: viral gene expression, tumor cell phenotype, and the role of the lymphoid stroma. Semin. Cancer Biol. 7: 165-174.